Ordering from outside the Americas?Switch to the EU store
We don't ship to your country yet. We ship across Europe and the Americas. You can keep browsing.

Peptency Academy · Guide

Regulatory status of peptide patches in the US, EU and UK

How are peptide patches classified and regulated in the US, the EU and the UK?

A 2025 white paper expects a microneedle and active substance sold as one unit to be classed as a combination or medicinal product, and calls the regulatory science for this product form immature, with limited explicit guidance. Source sentenceAbstract, first sentences: regulatory science for this emerging product form is immature and explicit guidance is limited.1 J Control Release 2025

Version 1Edited 6 sources

Regulatory content shown for: United States and the Americas.

Known, not known, contested

Known

  • The same paper identifies more than twenty critical quality attributes for the product form and ranks which of them need bespoke tests. Source sentenceAbstract, final sentences: a prioritisation exercise identifies the most pertinent attributes.1 J Control Release 2025

Not known

Contested

Nothing listed yet.

United States: drug, cosmetic and device lines

US

  • US law defines a cosmetic by use on the body for cleansing, beautifying or altering the appearance. Source sentencearticles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body or any part thereof for cleansing, beautifying, promoting attractiveness, or altering the appearance3 21 USC 321, definitions (drug, cosmetic)
  • A drug includes an article, other than food, intended to affect the structure or any function of the body. Source sentencearticles (other than food) intended to affect the structure or any function of the body of man or other animals3 21 USC 321, definitions (drug, cosmetic)
  • An FDA draft guidance of November 2019 covers pharmaceutical development and quality for transdermal and topical delivery systems, and it notes that microneedles carry considerations it does not address. (reported by FDA, read through a search summary) Source sentenceDraft guidance scope note: some transdermal systems, such as microneedles, have other considerations not addressed.4 FDA draft guidance, Transdermal and Topical Delivery Systems, Nov 2019
  • Aesthetic microneedling devices are Class II devices under 21 CFR 878.4430, cleared by 510(k). That class covers skin needling devices, not a patch that carries a drug. (reported by FDA, read through a search summary) Source sentenceFDA page: microneedling devices for aesthetic use are Class II under 21 CFR 878.4430.5 FDA, Microneedling devices page

United States: supplement patches

US

  • A 2026 editorial argues that patch dietary supplements sold as natural GLP-1 products break US law, because the Dietary Supplement Health and Education Act requires supplements to be swallowed. Source sentenceThe Dietary Supplement Health and Education Act specifies dietary supplement products must be swallowed, so all these products are illegal.6 Ann Pharmacother 2026
  • No certificates of analysis were posted for those products, and many carried no FDA disclaimer. Source sentenceNo certificates of analysis were posted, many products lacked the Food and Drug Administration disclaimer6 Ann Pharmacother 2026

How is a peptide patch classified under US law?

US law draws its lines by intended use. A product meant to affect the structure or any function of the body falls under the drug definition, and one used for cleansing, beautifying or altering appearance under the cosmetic definition. Source sentencearticles (other than food) intended to affect the structure or any function of the body of man or other animals3 21 USC 321, definitions (drug, cosmetic)

Published examples with IDs

  1. Analytical only (no biological model)Journal of controlled release : official journal of the Controlled Release Society 2025

    Classification, nomenclature and more than twenty critical quality attributes

    Design
    White paper by international stakeholders on regulatory science of microneedle product forms
    Molecule
    Microneedle product forms not established

    PubMed 39603537DOI

  2. Analytical only (no biological model)The Annals of pharmacotherapy 2026

    Count of patch products, listed ingredients and posted certificates of analysis

    Design
    Review of patch dietary supplement products sold as natural GLP-1 products
    Molecule
    Supplement patch products not established
    n
    25

    PubMed 41480958DOI

Sources

  1. 1J Control Release 2025 accessed 11 Nov 2026
  2. 2PubMed search for transdermal patch without microneedles, 11 November 2026 accessed 11 Nov 2026
  3. 321 USC 321, definitions (drug, cosmetic) accessed 11 Nov 2026
  4. 4FDA draft guidance, Transdermal and Topical Delivery Systems, Nov 2019 accessed 11 Nov 2026
  5. 5FDA, Microneedling devices page accessed 11 Nov 2026
  6. 6Ann Pharmacother 2026 accessed 11 Nov 2026

About this page

Research-use information. This library summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.

Reviewed by the Peptency editorial process. Version 1, edited 11 November 2026, 6 sources.

Cite this page: Peptency Academy. Regulatory status of peptide patches in the US, EU and UK. Version 1./us/academy/guides/peptide-patch-regulatory-status-us-eu-uk/